CAPR - Capricor and Lonza tie up in DMD development

Clinical-stage biotechnology company Capricor Therapeutics (CAPR) and Lonza have entered into an agreement for the development of CAP-1002, its leading clinical asset using allogeneic cardiosphere-derived cells ((CDC)) technology for the treatment of Duchenne Muscular Dystrophy ((DMD)) and complications arising from COVID-19.CAP-1002 completed the positive HOPE-2 phase 2 clinical trial and has been granted orphan drug designation by the FDA for the treatment of DMD.The agreement aims to expand Capricor’s manufacturing capacity for potential late-stage clinical trials and commercialization.Operations will begin with a tech-transfer to Lonza’s Houston center of excellence, where Lonza will perform process development activities for late-clinical and commercial-scale GMP manufacturing of CAP-1002.

For further details see:

Capricor and Lonza tie up in DMD development